Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome

• Published in: Cancer research (Chicago, Ill.) Vol. 80; no. 14; pp. 2996 - 3008
• Main Authors: Kikuchi, Hiroshi, Maishi, Nako, Annan, Dorcas A., Alam, Mohammad Towfik, Dawood, Randa Ibrahim Hassan, Sato, Masumi, Morimoto, Masahiro, Takeda, Ryo, Ishizuka, Keita, Matsumoto, Ryuji, Akino, Tomoshige, Tsuchiya, Kunihiko, Abe, Takashige, Osawa, Takahiro, Miyajima, Naoto, Maruyama, Satoru, Harabayashi, Toru, Azuma, Manabu, Yamashiro, Katsushige, Ameda, Kaname, Kashiwagi, Akira, Matsuno, Yoshihiro, Hida, Yasuhiro, Shinohara, Nobuo, Hida, Kyoko
• Format: Journal Article
• Language: English
• Published: 15.07.2020
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-19-3791

Abstract Tumor endothelial cells (TEC) lining tumor blood vessels actively contribute to tumor progression and metastasis. In addition to tumor cells, TEC may develop drug resistance during cancer treatment, allowing the tumor cells to survive chemotherapy and metastasize. We previously reported that TECs resist paclitaxel treatment via upregulation of ABCB1. However, whether TEC phenotypes are altered by anticancer drugs remains to be clarified. Here, we show that ABCB1 expression increases after chemotherapy in urothelial carcinoma cases. The ratio of ABCB1-positive TEC before and after first-line chemotherapy in urothelial carcinoma tissues (n = 66) was analyzed by ABCB1 and CD31 immunostaining. In 42 cases (64%), this ratio increased after first-line chemotherapy. Chemotherapy elevated ABCB1 expression in endothelial cells by increasing tumor IL8 secretion. In clinical cases, ABCB1 expression in TEC correlated with IL8 expression in tumor cells after first-line chemotherapy, leading to poor prognosis. In vivo, the ABCB1 inhibitor combined with paclitaxel reduced tumor growth and metastasis compared with paclitaxel alone. Chemotherapy is suggested to cause inflammatory changes in tumors, inducing ABCB1 expression in TEC and conferring drug resistance. Overall, these findings indicate that TEC can survive during chemotherapy and provide a gateway for cancer metastasis. Targeting ABCB1 in TEC represents a novel strategy to overcome cancer drug resistance. Significance: These findings show that inhibition of ABCB1 in tumor endothelial cells may improve clinical outcome, where ABCB1 expression contributes to drug resistance and metastasis following first-line chemotherapy.